证券代码：835892 证券简称：中科美菱 公告编号：2023-054 综上，我们对《关于 2023 年半年度募集资金存放与实际使用情况专项报告 的议案》发表明确的同意意见。 二、《关于对四川长虹集团财务有限公司风险评估报告的议案》的独立意见 根据中国银行保险监督管理委员会《企业集团财务公司管理办法》及《公司 章程》等相关规定，我们作为公司的独立董事，认真审阅董事会提交的《关于对 四川长虹集团财务有限公司的风险评估报告》及四川长虹集团财务有限公司（以 下简称"长虹财务公司"）的相关材料后，发表独立意见如下： 中科美菱低温科技股份有限公司 独立董事关于第三届董事会第十九次会议相关事项的独立意见 本公司及董事会全体成员保证公告内容的真实、准确和完整，没有虚假记载、 误导性陈述或者重大遗漏，并对其内容的真实性、准确性和完整性承担个别及连 带法律责任。 中科美菱低温科技股份有限公司（以下简称"公司"）于 2023 年 8 月 11 日 召开第三届董事会第十九次会议，根据《公司法》《证券法》《北京证券交易所上 市公司持续监管办法（试行）》《北京证券交易所股票上市规则（试行）》《北京证 券交易所上市公司持续监管指引第 1 ...

证券代码：835892 证券简称：中科美菱 公告编号：2023-049 中科美菱低温科技股份有限公司 第三届监事会第十三次会议决议公告 本公司及监事会全体成员保证公告内容的真实、准确和完整，没有虚假记 载、误导性陈述或者重大遗漏，并对其内容的真实性、准确性和完整性承担个 别及连带法律责任。 一、会议召开和出席情况 （一）会议召开情况 5.会议主持人：监事会主席杨鲲先生 6.召开情况合法、合规、合章程性说明： 本次会议的召集与召开、议案的审议程序等，均符合《公司法》《证券法》 《公司章程》及相关法律、法规、规范性文件的规定。 根据北京证券交易所发布的《北京证券交易所股票上市规则（试行）》的 要求，公司监事会对公司《2023 年半年度报告及摘要》进行了审核，并发表审 核意见如下： 1.会议召开时间：2023 年 8 月 11 日 2.会议召开地点：公司会议室 3.会议召开方式：现场方式 4.发出监事会会议通知的时间和方式：2023 年 8 月 1 日以电子邮件方式发出 1、公司《2023 年半年度报告及摘要》编制和审议程序符合法律法规、中 国证券监督管理委员会、北京证券交易所的规定和公司章程、公司内部管理制 度的 ...

证券代码：835892 证券简称：中科美菱 公告编号：2023-053 中科美菱低温科技股份有限公司 关于对四川长虹集团财务有限公司的风险评估报告 本公司及董事会全体成员保证公告内容的真实、准确和完整，没有虚假 记载、误导性陈述或者重大遗漏，并对其内容的真实性、准确性和完整性承 担个别及连带法律责任。 根据《企业集团财务公司管理办法》等相关规定和要求，中科美菱低温科技 股份有限公司（以下简称"公司"、"本公司"）通过查验四川长虹集团财务有 限公司(以下简称"长虹财务公司")的《金融许可证》《企业法人营业执照》等 证件资料，取得并审阅长虹财务公司包括资产负债表、利润表、现金流量表等在 内的定期财务会计报表（经审计），对其经营资质、业务和风险状况进行了评估， 现将有关风险评估情况报告如下： 各持股14.96%。法人代表：胡嘉，注册地址：绵阳高新区绵兴东路35号。长虹财 务公司统一社会信用代码：91510700076120682K。 经银保监会批准，长虹财务公司可开办以下业务：1、对成员单位办理财务 和融资顾问、信用鉴证及相关的咨询、代理业务；2、协助成员单位实现交易款 项的收付；3、经批准的保险代理业务；4、对成 ...

证券代码：835892 证券简称：中科美菱 公告编号：2023-052 中科美菱低温科技股份有限公司 募集资金存放与实际使用情况的专项报告 本公司及董事会全体成员保证公告内容的真实、准确和完整，没有虚假记 载、误导性陈述或者重大遗漏，并对其内容的真实性、准确性和完整性承担个 别及连带法律责任。 一、募集资金基本情况 （一）募集资金金额及到位时间 根据中国证券监督管理委员会《关于同意中科美菱低温科技股份有限公司 向不特定合格投资者公开发行股票注册的批复》（证监许可[2022]2182 号），公 司首次公开发行 24,182,734 股人民币普通股股票（A 股），每股面值 1 元，发 行价格人民币 16 元/股，募集资金合计人民币 386,923,744.00 元。本次募集 资金应支付承销费用、保荐费用人民币 19,407,867.71 元（不含税），其中公 司募集资金到账前已使用自有资金支付保荐费用人民币 943,396.23 元（不含 税），另 18,464,471.48 元（不含税）保荐费用自公司募集资金中扣除，扣除 支付的承销保荐费用后实际转入公司募集资金账户金额为 368,459,272.52 元 （含 ...

Financial Performance - The company's operating revenue for the first half of 2023 was ¥144,766,155.52, a decrease of 38.58% compared to ¥235,704,905.75 in the same period last year[28]. - The net profit attributable to shareholders was ¥8,290,186.98, down 79.92% from ¥41,290,315.92 year-on-year[28]. - The gross profit margin decreased to 37.60% from 38.63% in the previous year[28]. - The company achieved a net cash flow from operating activities of -¥13,679,152.09, an improvement of 39.87% compared to -¥22,750,957.05 in the previous year[30]. - The weighted average return on equity based on net profit attributable to shareholders was 1.42%, down from 15.74% in the previous year[28]. - The company reported a total comprehensive income of CNY 15,294,513.53 for the current period, compared to a comprehensive income of CNY 45,123,065.86 in the previous period, indicating a significant decline[152]. Assets and Liabilities - The total assets at the end of the reporting period were ¥752,735,816.90, a decrease of 6.74% from ¥807,110,596.75 at the end of the previous year[29]. - The total liabilities decreased by 22.45% to ¥159,723,407.32 from ¥205,972,761.11 year-on-year[29]. - The company's cash and cash equivalents at the end of the period amount to CNY 529,343,701.66, accounting for 70.32% of total assets, down from 72.12% at the end of the previous year[47]. - Total current assets decreased to CNY 603.51 million as of June 30, 2023, down from CNY 649.45 million at the end of 2022, representing a decline of approximately 7.06%[121]. - Total liabilities decreased to CNY 159.72 million as of June 30, 2023, from CNY 205.97 million at the end of 2022, reflecting a decline of about 22.43%[123]. Market and Product Development - The company launched new products at the 87th China International Medical Equipment Fair, including the RuiGu series high-speed refrigerated centrifuge and the third-generation RuiLian series refrigerators[7]. - The company is focusing on expanding its overseas market presence through participation in international exhibitions[39]. - The company is enhancing its product quality and production efficiency through continuous improvement initiatives[41]. - The company has developed a new generation of refrigeration technology with a 100% localization rate for components[40]. - The company is focusing on market expansion and new product development to enhance future growth prospects[130]. Research and Development - The company has obtained 67 new intellectual property rights in the first half of 2023, including 1 invention patent[40]. - Research and development expenses for the first half of 2023 were CNY 16.44 million, comparable to CNY 16.55 million in the first half of 2022, indicating a stable investment in innovation[130]. - The company is investing RMB 500 million in R&D for new low-temperature technology, aiming to launch two new products by Q4 2023[181]. Financial Management and Investments - The company has implemented a new marketing information management system to enhance operational efficiency[44]. - The company is focusing on financial derivative investments, including options and swaps, to enhance the returns of its structured deposit products[66]. - The company reported cash inflow from investment activities of CNY 486,990,993.50, significantly higher than CNY 103,827,533.81 in the same period last year[137]. - The company has raised a total of RMB 386,923,744.00 from the issuance of 24,182,734 shares at a price of RMB 16 per share[103]. Employee and Organizational Changes - The total number of employees decreased from 746 to 627, representing a reduction of approximately 15.9%[114]. - The company has established a comprehensive safety management system, conducting 42 safety training sessions and 35 safety training sessions for related parties during the reporting period[72]. - The company has implemented a robust employee rights protection system, including performance assessment and welfare management, to ensure employee satisfaction and legal rights[71]. Legal and Compliance Issues - The company reported a total of 10,172,743.04 yuan in litigation and arbitration matters, accounting for 1.72% of its net assets[79]. - The company is involved in an ongoing construction contract dispute with Zhejiang Tereis Pharmaceutical Co., Ltd., with an amount of 5,603,675.00 yuan at stake, representing 0.94% of its net assets[81]. - The company has not experienced significant changes in major risks during the reporting period[75]. Corporate Governance and Shareholder Information - The company has established a comprehensive internal control system to ensure compliance with information disclosure and corporate governance[70]. - The top two shareholders hold a combined 67.61% of the company's shares, with Changhong Meiling Co., Ltd. holding 47.45% and Zhongke Xianxing (Beijing) Asset Management Co., Ltd. holding 20.16%[101]. - The company has not experienced any changes in controlling shareholders or actual controllers during the reporting period[103].

证券代码：835892 证券简称：中科美菱 公告编号：2023-045 中科美菱低温科技股份有限公司 投资者关系活动记录表 本公司及董事会全体成员保证公告内容的真实、准确和完整，没有虚假 记载、误导性陈述或者重大遗漏，并对其内容的真实性、准确性和完整性承 担个别及连带法律责任。 一、投资者关系活动类型 特定对象调研 □业绩说明会 □媒体采访 □现场参观 □新闻发布会 □分析师会议 □路演活动 其他（请文字说明其他活动内容） 二、投资者关系活动情况 （一）活动时间、地点 中科美菱低温科技股份有限公司（以下简称"公司"）于 2023 年 6 月 7 日 -6 月 8 日在安徽省合肥市经济技术开发区紫石路 1862 号中科美菱低温科技股份 有限公司董事会办公室举办了投资者调研活动。 （二）参与单位 东北证券、德福资本 （三）上市公司接待人员 公司董事会秘书、财务负责人：徐胜朝先生 三、投资者关系活动主要内容 本次投资者调研活动通过现场会议、电话会议的交流方式就投资者关心的问 题进行了回答，主要问题及回复情况如下： 问题 1：请问公司产品核心技术是什么？技术和产品研发是否具备市场优势？ 回复：公司自成立以来高度重视低 ...

Financial Performance - Operating revenue for Q1 2023 was ¥76,810,113.89, a decrease of 41.44% year-on-year from ¥131,171,039.95 in Q1 2022[14] - Net profit attributable to shareholders for Q1 2023 was ¥5,290,570.22, down 79.12% from ¥25,343,047.44 in the same period last year[14] - Basic earnings per share decreased by 84.34% to ¥0.0547 in Q1 2023, compared to ¥0.3493 in Q1 2022[14] - Total operating revenue for Q1 2023 was CNY 76,810,113.89, a decrease of 41.5% compared to CNY 131,171,039.95 in Q1 2022[44] - Net profit for Q1 2023 was CNY 5,290,570.22, a decline of 79.1% from CNY 25,343,047.44 in Q1 2022[46] - Basic and diluted earnings per share for Q1 2023 were CNY 0.0547, compared to CNY 0.3493 in Q1 2022[46] - The total comprehensive income for Q1 2023 was CNY 10,004,504.66, compared to CNY 26,961,415.29 in Q1 2022, indicating a significant decline[50] Cash Flow - The net cash flow from operating activities increased by 181.31% to ¥10,886,241.11, compared to a negative cash flow of ¥13,389,261.33 in the previous year[14] - Cash flow from operating activities generated a net amount of CNY 10,886,241.11, recovering from a negative cash flow of CNY -13,389,261.33 in Q1 2022[51] - Total cash inflow from operating activities was CNY 113,368,350.44, an increase of 9.0% from CNY 103,067,482.34 in Q1 2022[51] - Cash outflow from operating activities decreased to CNY 102,482,109.33 from CNY 116,456,743.67, reflecting a reduction of 12.0%[51] - The net cash flow from financing activities was -$4,037,660.20, a decline from a positive net cash flow of $10,146,527.78 in the previous year[55] - The total cash and cash equivalents at the end of the period were $430,429,534.93, up from $177,941,981.52 at the end of the same quarter last year[55] Assets and Liabilities - Total assets as of March 31, 2023, amounted to ¥813,520,667.67, representing a 0.79% increase compared to the end of 2022[14] - The total liabilities to assets ratio (consolidated) was 25.38%, slightly down from 25.52% at the end of 2022[14] - The company's total liabilities stood at ¥206,474,159.01, which is a marginal increase from ¥205,972,761.11, showing a growth of about 0.2%[38] - The company's equity attributable to shareholders increased to ¥607,046,508.66 from ¥601,137,835.64, marking an increase of approximately 1%[38] - The company's cash and cash equivalents decreased to ¥495,099,137.70 from ¥582,090,924.03, representing a decline of about 15%[36] Shareholder Information - The number of ordinary shareholders as of the report date was 9,439, with a total share capital of 96,730,934 shares[23] - The largest shareholder, Changhong Meiling Co., Ltd., holds 45,900,000 shares, representing 47.45% of total shares[24] - The second largest shareholder, Zhongke Xianxing (Beijing) Asset Management Co., Ltd., holds 19,500,000 shares, accounting for 20.16%[24] - The total shares held by the top ten shareholders amount to 71,492,439, which is 73.91% of the total shares[25] Legal and Compliance - A lawsuit involving Zhejiang Terwis Pharmaceutical Co., Ltd. claims an amount of 5,603,675 yuan, which represents 0.92% of the company's net assets[30] - The company has recognized a provision for potential repair costs related to the ongoing lawsuit, indicating a proactive approach to financial risk management[30] - The company has not engaged in any external borrowing or significant related party transactions during the reporting period[28] - There are no major external guarantees or asset pledges reported for the current period[28] - The company has fulfilled all disclosed commitments in a timely manner, ensuring compliance with regulatory requirements[28] Research and Development - Research and development expenses increased by ¥1,612,500, reflecting a focus on enhancing growth momentum despite reduced revenue[15] - The company plans to accelerate the development of strategic products such as biological safety cabinets and centrifuges, while expanding market channels[15] - Research and development expenses for Q1 2023 were CNY 8,189,437.30, an increase of 24.6% from CNY 6,576,964.88 in Q1 2022[45] Inventory and Receivables - The company's inventory increased to ¥49,991,209.24 from ¥48,074,736.13, reflecting a growth of about 4%[36] - The company's accounts receivable decreased to ¥4,202,695.38 from ¥5,852,225.38, indicating a decline of approximately 28%[36]

证券代码：835892 证券简称：中科美菱 公告编号：2023-031 中科美菱低温科技股份有限公司 2022 年年度报告业绩说明会预告公告 本公司及董事会全体成员保证公告内容的真实、准确和完整，没有虚假记载、 误导性陈述或者重大遗漏，并对其内容的真实性、准确性和完整性承担个别及连 带法律责任。 一、说明会类型 中科美菱低温科技股份有限公司（以下简称"公司"）于 2023 年 3 月 17 日 在北京证券交易所信息披露平台（www.bse.cn）披露了《2022 年年度报告》（公 告编号：2023-018）及《2022 年年度报告摘要》（公告编号：2023-019），为方 便广大投资者更深入了解公司 2022 年年度经营业绩的具体情况，加强与投资者 的互动交流，公司拟召开 2022 年年度报告业绩说明会。 二、说明会召开的时间、地点 （一）会议召开时间：2023 年 4 月 7 日（星期五）15:00-17:00。 （二）会议召开地点 本次业绩说明会将采用网络远程的方式举行，投资者可登陆全景网"投资者 关系互动平台"（http://ir.p5w.net）参与本次年报业绩说明会。 三、参加人员 公司董事、总经理 ...

Company Listing and Market Presence - Zhongke Meiling successfully listed on the Beijing Stock Exchange on October 18, 2022[3] - The company participated in several major exhibitions, including CMEF and the 14th Biobanking Conference, to enhance market presence[5] - The company aims to enhance its position as a leading provider of customized solutions in the biomedical field, focusing on low-temperature storage and medical cold chain equipment[38] - The company has focused on expanding its overseas marketing efforts, targeting new customer development in blank market areas[46] - The company is focused on expanding its domestic and international market presence, enhancing its distribution network and customer base[110] Financial Performance - The company's operating revenue for 2022 was ¥406,489,091.83, a decrease of 12.64% compared to ¥465,285,460.79 in 2021[27] - The net profit attributable to shareholders for 2022 was ¥52,586,940.63, down 22.09% from ¥67,493,509.40 in 2021[27] - The gross profit margin improved to 38.17% in 2022 from 36.35% in 2021[27] - Total assets increased by 55.27% to ¥807,126,097.66 at the end of 2022, compared to ¥519,833,682.23 at the end of 2021[28] - The company's total liabilities decreased by 25.93% to ¥205,972,761.11 in 2022 from ¥278,071,693.46 in 2021[28] - The net asset attributable to shareholders rose by 148.66% to ¥601,153,336.55 in 2022, compared to ¥241,761,988.77 in 2021[28] - The cash flow from operating activities was negative at -¥38,010,376.20 in 2022, a decline of 154.20% from ¥70,126,648.10 in 2021[29] - The company reported a basic earnings per share of ¥0.6867 in 2022, down 26.19% from ¥0.9303 in 2021[27] Research and Development - Research and development expenses increased by 14.13% to 28.27 million yuan in 2022, with a total of 172 intellectual property applications filed, a 350% increase from 2021[45] - The company completed the development of a new generation of medical refrigerators and a series of ultra-low temperature products, which are now entering the overseas certification phase[45] - The company is actively involved in the research and development of low-temperature refrigeration equipment through its subsidiary, Tuoxing Technology[80] - R&D expenditure for 2022 amounted to ¥28,272,829.67, representing 6.96% of total revenue, up from 5.32% in the previous year[87] - The number of R&D personnel increased from 101 to 128, with the proportion of R&D staff in total employees rising from 17.16% to 22.49%[89] Risk Management and Governance - Zhongke Meiling faces market risks due to the lack of strict industry standards, leading to increased competition and potential profit margin decline[10] - Management emphasizes the need for improved internal controls and governance as the company expands its operations[11] - The company has established measures to reduce related party transactions to mitigate risks associated with its controlling shareholder[10] - The company has implemented a governance structure to mitigate risks associated with the actual controller's influence on major management decisions[116] - The company has committed to optimizing its internal control system to meet the demands of its expanding operations[121] Legal and Compliance Matters - The company is facing a lawsuit with a claim amount of CNY 5,603,675, which represents 0.93% of the net assets at the end of the reporting period[129] - The company won a lawsuit against Zhengqi International Commercial Factoring Co., Ltd. regarding a factoring contract dispute, with a claim amount of ¥1,923,791.34[131] - The company also won a lawsuit against Qingdao Haier Biomedical Co., Ltd. concerning a design patent infringement, where the court ruled that the accused design did not infringe on the patent rights[136] - The total amount involved in the lawsuits is ¥2,923,791.34, with the company not bearing any compensation responsibility[135] - The company has confirmed that there are no false records or misleading statements in the application documents for listing on the Beijing Stock Exchange[189] Corporate Social Responsibility - The company actively participated in social welfare activities, donating nearly 450,000 RMB in scholarships to support education during the pandemic[106] - In 2022, the company organized 170 safety training sessions and 73 safety training sessions for related parties, aiming to improve overall safety awareness[104] Future Outlook and Strategy - The company anticipates steady growth in the medical device market in 2023, driven by increased consumer spending and the ongoing development of the healthcare system[108] - The company plans to focus on the life sciences sector, exiting low-margin household health products to enhance competitiveness[109] - The company is exploring new strategies for market expansion and potential acquisitions to drive future growth[91] - The company is committed to enhancing production efficiency and controlling costs in the development of its medical refrigeration products[93] Financial Commitments and Transactions - The company has provided guarantees totaling CNY 180 million for bank credit applications during the reporting period[120] - The company has a total debt guarantee amount for entities with asset-liability ratios exceeding 70% of ¥180,000,000[141] - The company has engaged in significant financial transactions with Changhong Financial, including loans and deposits, which are under ongoing review[147] - The company is focused on maintaining compliance with financial regulations and commitments to reduce related party transactions[151]

Financial Performance - The company reported a revenue of ¥406,489,091.83 for the year 2022, a decrease of 12.64% compared to ¥465,285,460.79 in the previous year[4] - Net profit attributable to shareholders was ¥52,586,940.63, down 22.09% from ¥67,493,509.40 in the prior year[4] - The net profit after deducting non-recurring gains and losses decreased by 37.30%, amounting to ¥39,149,709.74[4] - Basic earnings per share decreased by 26.19% to ¥0.6867 from ¥0.9303[4] Assets and Equity - Total assets increased by 55.27% to ¥807,126,097.66 from ¥519,833,682.23 at the beginning of the period[4] - Shareholders' equity attributable to the company surged by 148.66% to ¥601,153,336.55 from ¥241,761,988.77[4] - The company's share capital increased by 33.33% to ¥96,730,934.00 from ¥72,548,200.00[4] Operational Changes - The company expanded its R&D and sales teams, leading to increased R&D and sales expenses, which impacted net profit[6] - The decline in revenue was primarily due to reduced market demand for low-temperature storage equipment and changes in product sales structure influenced by pandemic control measures[6] Cautionary Note - The company warns that the financial data presented is preliminary and has not been audited, advising investors to be cautious[7]